Updated: 8/1/2017

Alcoholic Liver Disease

Topic
Review Topic
0
0
Questions
3
0
0
Evidence
2
0
0
Videos
2
Introduction
  • Chronic use results in three main disease processes
    • steatosis (fatty change)      
      • reversible state with cessation of alcohol
      • macrovesicular fatty change that can develop over the short term with moderate alcohol intake
        • contrast this from non-alcoholic fatty liver disease (NAFLD)
          • Patient's do not abuse alcohol, tend to be overweight and usually have an ALT > AST 
    • hepatitis
      • reversible state with cessation of alcohol
      • hepatocytes are enlarged with eosinophilic inclusions (Mallory bodies)
        • Mallory bodies are damaged intermediate filaments (cytokeratin) in hepatocytes
          • neutrophils are present
          • damage mediated by acetaldehyde
          • requires many years of continuous alcohol intake
        • cirrhosis
  • Pathophysiology
    • ethanol metabolism
      • presence of decreased NAD levels play a major role in altered metabolism
  • Risk factors
    • length of use
    • amount
    • women > men
Presentation
  • Symptoms and physical exam
    • fatty change
      • tender hepatomegaly
      • afebrile
    • hepatitis
      • tender hepatomegaly
      • fever
      • acities
    • cirrhosis
      • abdominal distention
      • altered mental status
      • tremor
      • fetor hepatis (foul smell of amines)
Evaluation
  • Labs
    • elevated AST and ALT
      • AST:ALT > 2 suggests alcoholic hepatitis
        • other liver pathologies have ALT > AST
        • inversed because AST is found in the mitochondria and EtOH is a mitochondiral toxin
    • absolute neutrophilic leukocytosis
      • seen in hepatitis but not fatty change
    • fasting hypoglycemia
    • ↑ anion gap metabolic acidosis
    • hypertriglyceridemia
    • hyperuricemia
    • thrombocytopenia
    • ↑ γ-gluamyltransferase
      • secondary to EtOH induced hyperplasia of the smooth ER
Treatment
  • Lifestyle
    • cessation of alcohol
  • Pharmacologic
    • steroids
  • Operative
    • transplant
Prognosis, Prevention, and Complications
  • Prognosis ranges from good to poor depending on early intervention and alcohol cessation
  • Early alcoholic liver changes (i.e. fatty liver) are reversible with lifestyle changes
  • Chronic hepatitis increases risk of hepatocellular carcinoma
  • Death from fulminant liver failure
 

Please rate topic.

Average 3.0 of 4 Ratings

Thank you for rating! Please vote below and help us build the most advanced adaptive learning platform in medicine

The complexity of this topic is appropriate for?
How important is this topic for board examinations?
How important is this topic for clinical practice?
Questions (3)
QUESTIONS
1 of 3
  • 1
  • 2
  • 3
Lab Values
Blood, Plasma, Serum Reference Range
ALT 8-20 U/L
Amylase, serum 25-125 U/L
AST 8-20 U/L
Bilirubin, serum (adult) Total // Direct 0.1-1.0 mg/dL // 0.0-0.3 mg/dL
Calcium, serum (Ca2+) 8.4-10.2 mg/dL
Cholesterol, serum Rec: < 200 mg/dL
Cortisol, serum 0800 h: 5-23 μg/dL //1600 h:
3-15 μg/dL
2000 h: ≤ 50% of 0800 h
Creatine kinase, serum Male: 25-90 U/L
Female: 10-70 U/L
Creatinine, serum 0.6-1.2 mg/dL
Electrolytes, serum  
Sodium (Na+) 136-145 mEq/L
Chloride (Cl-) 95-105 mEq/L
Potassium (K+) 3.5-5.0 mEq/L
Bicarbonate (HCO3-) 22-28 mEq/L
Magnesium (Mg2+) 1.5-2.0 mEq/L
Estriol, total, serum (in pregnancy)  
24-28 wks // 32-36 wks 30-170 ng/mL // 60-280 ng/mL
28-32 wk // 36-40 wks 40-220 ng/mL // 80-350 ng/mL
Ferritin, serum Male: 15-200 ng/mL
Female: 12-150 ng/mL
Follicle-stimulating hormone, serum/plasma Male: 4-25 mIU/mL
Female: premenopause: 4-30 mIU/mL
midcycle peak: 10-90 mIU/mL
postmenopause: 40-250
pH 7.35-7.45
PCO2 33-45 mmHg
PO2 75-105 mmHg
Glucose, serum Fasting: 70-110 mg/dL
2-h postprandial:<120 mg/dL
Growth hormone - arginine stimulation Fasting: <5 ng/mL
Provocative stimuli: > 7ng/mL
Immunoglobulins, serum  
IgA 76-390 mg/dL
IgE 0-380 IU/mL
IgG 650-1500 mg/dL
IgM 40-345 mg/dL
Iron 50-170 μg/dL
Lactate dehydrogenase, serum 45-90 U/L
Luteinizing hormone, serum/plasma Male: 6-23 mIU/mL
Female: follicular phase: 5-30 mIU/mL
midcycle: 75-150 mIU/mL
postmenopause 30-200 mIU/mL
Osmolality, serum 275-295 mOsmol/kd H2O
Parathyroid hormone, serume, N-terminal 230-630 pg/mL
Phosphatase (alkaline), serum (p-NPP at 30° C) 20-70 U/L
Phosphorus (inorganic), serum 3.0-4.5 mg/dL
Prolactin, serum (hPRL) < 20 ng/mL
Proteins, serum  
Total (recumbent) 6.0-7.8 g/dL
Albumin 3.5-5.5 g/dL
Globulin 2.3-3.5 g/dL
Thyroid-stimulating hormone, serum or plasma .5-5.0 μU/mL
Thyroidal iodine (123I) uptake 8%-30% of administered dose/24h
Thyroxine (T4), serum 5-12 μg/dL
Triglycerides, serum 35-160 mg/dL
Triiodothyronine (T3), serum (RIA) 115-190 ng/dL
Triiodothyronine (T3) resin uptake 25%-35%
Urea nitrogen, serum 7-18 mg/dL
Uric acid, serum 3.0-8.2 mg/dL
Hematologic Reference Range
Bleeding time 2-7 minutes
Erythrocyte count Male: 4.3-5.9 million/mm3
Female: 3.5-5.5 million mm3
Erythrocyte sedimentation rate (Westergren) Male: 0-15 mm/h
Female: 0-20 mm/h
Hematocrit Male: 41%-53%
Female: 36%-46%
Hemoglobin A1c ≤ 6 %
Hemoglobin, blood Male: 13.5-17.5 g/dL
Female: 12.0-16.0 g/dL
Hemoglobin, plasma 1-4 mg/dL
Leukocyte count and differential  
Leukocyte count 4,500-11,000/mm3
Segmented neutrophils 54%-62%
Bands 3%-5%
Eosinophils 1%-3%
Basophils 0%-0.75%
Lymphocytes 25%-33%
Monocytes 3%-7%
Mean corpuscular hemoglobin 25.4-34.6 pg/cell
Mean corpuscular hemoglobin concentration 31%-36% Hb/cell
Mean corpuscular volume 80-100 μm3
Partial thromboplastin time (activated) 25-40 seconds
Platelet count 150,000-400,000/mm3
Prothrombin time 11-15 seconds
Reticulocyte count 0.5%-1.5% of red cells
Thrombin time < 2 seconds deviation from control
Volume  
Plasma Male: 25-43 mL/kg
Female: 28-45 mL/kg
Red cell Male: 20-36 mL/kg
Female: 19-31 mL/kg
Cerebrospinal Fluid Reference Range
Cell count 0-5/mm3
Chloride 118-132 mEq/L
Gamma globulin 3%-12% total proteins
Glucose 40-70 mg/dL
Pressure 70-180 mm H2O
Proteins, total < 40 mg/dL
Sweat Reference Range
Chloride 0-35 mmol/L
Urine  
Calcium 100-300 mg/24 h
Chloride Varies with intake
Creatinine clearance Male: 97-137 mL/min
Female: 88-128 mL/min
Estriol, total (in pregnancy)  
30 wks 6-18 mg/24 h
35 wks 9-28 mg/24 h
40 wks 13-42 mg/24 h
17-Hydroxycorticosteroids Male: 3.0-10.0 mg/24 h
Female: 2.0-8.0 mg/24 h
17-Ketosteroids, total Male: 8-20 mg/24 h
Female: 6-15 mg/24 h
Osmolality 50-1400 mOsmol/kg H2O
Oxalate 8-40 μg/mL
Potassium Varies with diet
Proteins, total < 150 mg/24 h
Sodium Varies with diet
Uric acid Varies with diet
Body Mass Index (BMI) Adult: 19-25 kg/m2
Calculator

Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK

(M1.GI.134) A 39-year-old Caucasian male presents for a physical exam. It is noticed that he has slight hepatomegaly. During the history, the patient states he drinks 7-8 beers daily. Biopsy of the liver is shown in Figure A. What is the primary mechanism for the abnormality seen in Figure A? Review Topic

QID: 101191
FIGURES:
1

Increased production of NAD

15%

(12/80)

2

Decreased production of NAD

42%

(34/80)

3

Increased fatty acid oxidation

16%

(13/80)

4

Increased synthesis and exportation of lipoproteins

6%

(5/80)

5

Increased uptake of fat

18%

(14/80)

M1

Select Answer to see Preferred Response

PREFERRED RESPONSE 2
ARTICLES (2)
VIDEOS (2)
Topic COMMENTS (10)

of images

Private Note